DTX 201

Drug Profile

DTX 201

Alternative Names: AAV-mediated Factor VIII gene therapy; DTX-201

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Dimension Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 09 Mar 2017 Dimension Therapeutics announces intention to submit IND application to USFDA for Haemophilia A by the end of 2017
  • 24 Mar 2016 Dimension Therapeutics has patent protection for DTX 201 (Dimension Therapeutics 10-K; March 2016)
  • 24 Mar 2016 Dimension Therapeutics has patents pending for DTX 201 (Dimension Therapeutics 10-K; March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top